ArticleAdvanced biomedical research2026
Barbaloin Attenuates Cerebral Ischemia and Reperfusion Injury in Rats and Inhibits Lipopolysaccharide-Stimulated Inflammatory Responses in BV2 Microglial Cells.
Article in Advanced biomedical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Barbaloin (BAR) is a naturally occurring bioactive anthracycline derived from the leaf exudates of aloe plants with a variety of biological and pharmacological properties. The aim of the present study was to investigate the neuroprotective effects of BAR against cerebral ischemia and reperfusion (I/R) injury in rats and the possible underlying mechanisms. Materials and Methods: Middle cerebral artery occlusion followed by reperfusion was used to induce cerebral I/R injury in rats, and BAR was administered intraperitoneally after the onset of ischemia. Results: We found that BAR remarkably improved neurological scores, reduced brain infarct volume, and inhibited neuronal apoptosis in cerebral I/R rats. Furthermore, BAR upregulated Bcl-2 protein levels and downregulated cleaved caspase-3, Bax, and inducible nitric oxide synthase (iNOS) in the ischemic cortex. I/R injury-induced increases in malondialdehyde content, and decreases in glutathione, glutathione peroxidase, and superoxide dismutase activities were significantly attenuated by BAR administration. Conclusion: Taken together, our data suggest that BAR possesses neuroprotective effects against cerebral I/R injury through antiapoptotic, antioxidative, and anti-inflammatory properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.